FILE - In this Aug. 6, 2015 file photo, Sarah Jessica Parker attends the Broadway opening night of "Hamilton" in New York. Parker said she is “disappointed, saddened and deeply concerned” by the price hike of the EpiPen. She has cut ties with the company that makes the emergency allergy treatment. (Photo by Charles Sykes/Invision/AP, File)

Sarah Jessica Parker ends EpiPen partnership after price hike

Actress Sarah Jessica Parker said she is "disappointed, saddened and deeply concerned" after the price of the EpiPen soared hundreds of dollars.

>> Read more trending stories  

The price of the product, which was less than $60 in 2007, rose to more than $600 recently. It is independently supplied by Mylan Pharmaceuticals.

"I do not condone this decision, and I have ended my relationship with Mylan as a direct result of it," Parker wrote on Instagram. "I hope (Mylan) will seriously reconsider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable for whom it is a life-saving necessity."

Parker, who was previously part of a campaign with Mylan, has a 13-year-old son, James, who has peanut allergies.

"The Epinephrine auto-injector is a vital part of our family's healthcare, as it is for the many who are at risk," Parker wrote.

A photo posted by SJP (@sarahjessicaparker) on

The drugmaker responded to criticism Thursday by announcing it would offer discounts for the EpiPen, including coupons covering up to $300 "for patients in health plans who face higher out-of-pocket costs." Critics maintained that an unchanging list price would ultimately leave consumers bearing most of the costs.

Thank you for reading the Springfield News-Sun and for supporting local journalism. Subscribers: log in for access to your daily ePaper and premium newsletters.

Thank you for supporting in-depth local journalism with your subscription to the Springfield News-Sun. Get more news when you want it with email newsletters just for subscribers. Sign up here.